Trial (Reference)
|
Year
|
Number of patients
|
Name of drug
|
Comparator
|
Daily maintenance dose (mg)
|
Follow-up (months)
|
Jadad scoring
|
---|
Anderson et al.12
|
1985
|
50
|
Metoprolol
|
Control
|
61
|
19
|
3
|
ANZ16
|
1997
|
415
|
Carvedilol
|
Placebo
|
12.5
|
19
|
4
|
BEST6
|
2001
|
2708
|
Bucindolol
|
Placebo
|
152
|
24
|
5
|
BHAT39
|
1986
|
3837
|
Propranolol
|
Placebo
|
180/240
|
25
|
5
|
Bristow et al.17
|
1994
|
139
|
Bucindolol
|
Placebo
|
12.5/50/200
|
3
|
5
|
Bristow et al.18
|
1996
|
345
|
Carvedilol
|
Placebo
|
12.5/25/50
|
6
|
5
|
Capricorn19
|
2001
|
1959
|
Carvedilol
|
Placebo
|
50
|
15.6
|
5
|
CIBIS II21
|
1999
|
2647
|
Bisoprolol
|
Placebo
|
10
|
15
|
5
|
CIBIS20
|
1994
|
641
|
Bisoprolol
|
Placebo
|
5
|
23
|
5
|
CILICARD33
|
2000
|
124
|
Celiprolol
|
Placebo
|
100
|
12
|
5
|
Colucci et al.22
|
1996
|
366
|
Carvedilol
|
Placebo
|
100
|
15
|
5
|
COPERNICUS8
|
2002
|
2289
|
Carvedilol
|
Placebo
|
50
|
10.4
|
5
|
De Milliano et al.34
|
2002
|
59
|
Metoprolol
|
Placebo
|
150
|
6
|
5
|
ELANDD35
|
2011
|
116
|
Nebivelol
|
Placebo
|
5/10
|
6
|
5
|
Engleimeir et al.23
|
1985
|
25
|
Metoprolol
|
Placebo
|
92
|
12
|
4
|
Fisher et al.24
|
1994
|
50
|
Metoprolol
|
Placebo
|
87
|
6
|
5
|
Hansteen V. et al.25
|
1982
|
560
|
Propranolol
|
Placebo
|
160
|
12
|
5
|
Krum et al.26
|
1995
|
49
|
Carvedilol
|
Placebo
|
50
|
4
|
5
|
MDC27
|
1993
|
383
|
Metoprolol
|
Placebo
|
108/115
|
18
|
3
|
MERIT-HF28
|
1999
|
3991
|
Metoprolol
|
Placebo
|
159/170
|
12
|
5
|
Metra et al.29
|
1994
|
40
|
Carvedilol
|
Placebo
|
50
|
4
|
4
|
Olsen et al.30
|
1995
|
60
|
Carvedilol
|
Placebo
|
81
|
4
|
5
|
Packer et al.31
|
1996
|
1094
|
Carvedilol
|
Placebo
|
60
|
6
|
5
|
Pollock et al.32
|
1990
|
19
|
Bucindolol
|
Placebo
|
200
|
3
|
4
|
RESOLVD36
|
2000
|
426
|
Metoprolol
|
Placebo
|
156
|
6
|
5
|
SENIORS14
|
2005
|
2128
|
Nebivelol
|
Placebo
|
7.7
|
21
|
5
|
Sturm37
|
2000
|
100
|
Atenolol
|
Placebo
|
89
|
24
|
5
|
UHLIR et al.38a
|
1997
|
91
|
Nebivelol
|
Placebo
|
2.5/5
|
3.5
|
5
|
Wisenbaugh et al.15
|
1993
|
24
|
Nebivelol
|
placebo
|
5
|
3
|
5
|
Woodley et al.13
|
1991
|
50
|
Bucindolol
|
Placebo
|
175
|
3
|
5
|
- ANZ: Australian/New Zealand Heart Failure Research Collaborative Group; BEST: Beta-blocker Bucindolol in patients with advanced chronic heart failure; CAPRICORN: Effect of carvedilol on outcome after myocardial infarction inpatients; COPRINCUS: Effect of Carvedilol on the Morbidity of Patients with Severe chronic Heart Failure; MDC: Metoprolol in Dilated Cardiomyopathy Trial study; Merit-HF: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; SENIORS: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure.